264 related articles for article (PubMed ID: 31156616)
1. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
2. Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiency.
Bakacs T; Mehrishi JN
Immunobiology; 2015 May; 220(5):624-5. PubMed ID: 25638260
[TBL] [Abstract][Full Text] [Related]
3. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
[TBL] [Abstract][Full Text] [Related]
4. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
5. Clinical Phenotypes and Immunological Characteristics of 18 Egyptian LRBA Deficiency Patients.
Meshaal S; El Hawary R; Adel R; Abd Elaziz D; Erfan A; Lotfy S; Hafez M; Hassan M; Johnson M; Rojas-Restrepo J; Gamez-Diaz L; Grimbacher B; Shoman W; Abdelmeguid Y; Boutros J; Galal N; El-Guindy N; Elmarsafy A
J Clin Immunol; 2020 Aug; 40(6):820-832. PubMed ID: 32506362
[TBL] [Abstract][Full Text] [Related]
6. Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma.
Retseck J; Nasr A; Lin Y; Lin H; Mendiratta P; Butterfield LH; Tarhini AA
J Transl Med; 2018 Jul; 16(1):184. PubMed ID: 29973204
[TBL] [Abstract][Full Text] [Related]
7. Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulation.
Alroqi FJ; Charbonnier LM; Baris S; Kiykim A; Chou J; Platt CD; Algassim A; Keles S; Al Saud BK; Alkuraya FS; Jordan M; Geha RS; Chatila TA
J Allergy Clin Immunol; 2018 Mar; 141(3):1050-1059.e10. PubMed ID: 28601686
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency.
Krone KA; Winant AJ; Vargas SO; Platt CD; Bartnikas LM; Janssen E; Lillehei C; Lee EY; Fishman MP; Casey A
Pediatr Pulmonol; 2021 Jul; 56(7):2232-2241. PubMed ID: 33710794
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
Gámez-Díaz L; Grimbacher B
Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
[TBL] [Abstract][Full Text] [Related]
10. Lessons from CTLA-4 deficiency and checkpoint inhibition.
Lo B; Abdel-Motal UM
Curr Opin Immunol; 2017 Dec; 49():14-19. PubMed ID: 28806575
[TBL] [Abstract][Full Text] [Related]
11. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
12. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
13. Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.
Hou TZ; Verma N; Wanders J; Kennedy A; Soskic B; Janman D; Halliday N; Rowshanravan B; Worth A; Qasim W; Baxendale H; Stauss H; Seneviratne S; Neth O; Olbrich P; Hambleton S; Arkwright PD; Burns SO; Walker LS; Sansom DM
Blood; 2017 Mar; 129(11):1458-1468. PubMed ID: 28159733
[TBL] [Abstract][Full Text] [Related]
14. Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.
Bratanič N; Kovač J; Pohar K; Trebušak Podkrajšek K; Ihan A; Battelino T; Avbelj Stefanija M
Orphanet J Rare Dis; 2017 Jul; 12(1):131. PubMed ID: 28720148
[TBL] [Abstract][Full Text] [Related]
15. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
[TBL] [Abstract][Full Text] [Related]
16. Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency.
Catak MC; Akcam B; Bilgic Eltan S; Babayeva R; Karakus IS; Akgun G; Baser D; Bulutoglu A; Bayram F; Kasap N; Kiykim A; Hancioglu G; Kokcu Karadag SI; Kendir Demirkol Y; Ozen S; Cekic S; Ozcan D; Edeer Karaca N; Sasihuseyinoglu AS; Cansever M; Ozek Yucel E; Tamay Z; Altintas DU; Aydogmus C; Celmeli F; Cokugras H; Gulez N; Genel F; Metin A; Guner SN; Kutukculer N; Keles S; Reisli I; Kilic SS; Yildiran A; Karakoc-Aydiner E; Lo B; Ozen A; Baris S
Allergy; 2022 Oct; 77(10):3108-3123. PubMed ID: 35491430
[TBL] [Abstract][Full Text] [Related]
17. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive comparison between 222 CTLA-4 haploinsufficiency and 212 LRBA deficiency patients: a systematic review.
Jamee M; Hosseinzadeh S; Sharifinejad N; Zaki-Dizaji M; Matloubi M; Hasani M; Baris S; Alsabbagh M; Lo B; Azizi G
Clin Exp Immunol; 2021 Jul; 205(1):28-43. PubMed ID: 33788257
[TBL] [Abstract][Full Text] [Related]
19. Preponderance of
Siggs OM; Russell A; Singh-Grewal D; Wong M; Chan P; Craig ME; O'Loughlin T; Stormon M; Goodnow CC
Front Immunol; 2019; 10():1544. PubMed ID: 31396201
[TBL] [Abstract][Full Text] [Related]
20. Heterozygous
Mahat U; Ambani NM; Rotz SJ; Radhakrishnan K
Pediatr Hematol Oncol; 2021 Oct; 38(7):658-662. PubMed ID: 33900894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
